Professor Steven Petrou
Steve is a PhD trained neuroscientist who focuses on disease biology and therapeutics of neurogenetic disorders. His interdisciplinary research includes ion channel biophysics, neurophysiology, animal models of neurogenetic disorders, molecular and cellular biology, computational biology, and instrumentation. He is a globally recognised leader in the field of ion channel disease, with a particular focus on rare and devastating neurodevelopmental disorders affecting infants and young children.
In 2015 he was admitted to the Australian Academy of Health and Medical Sciences (FAHMS). Steve is passionate about consumer engagement and public outreach and regularly participates in genetic epilepsy family forums and public lectures.
- Director of The Florey
- Steve has attracted over $50 million in research support, including $14 million as Chief Investigator on an NHMRC Program Grant
- Steve holds over 10 patents
- Steve has published extensively and has an h-index of 55
- Steve is the co-founder and Chief Scientific Officer of US based biotechs, RogCon Inc and Praxis Precision Medicines, companies pioneering breakthroughs in epileptic and neurological as well as psychiatric disorders